20 results about "Invasion metastasis" patented technology

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

The invention discloses a drug curative effect prediction model for probiotic combined treatment of colon cancer, a construction method and a device, and belongs to the technical field of biological medicines. The invention provides a method for treating colon cancer through combination of probiotics, a mathematical model is constructed at the same time, the influence of an alpha value on the speed of a system tending to be balanced is analyzed, and it is obtained that initial conditions only influence the speed of the system tending to be balanced and do not influence the stability of the system. Meanwhile, the analysis of the influence of the drug dosage on the immune system finds that the tumor removal time can be obviously shortened by the full-dose triple therapy, the curative effect is obviously improved compared with that of a single drug or double drugs, and the action mechanism of a combined therapy scheme is disclosed: the invasion and transfer rate of CD4 + T cells can be obviously improved by increasing probiotics while the chemical immunotherapy dosage is fixed; the anti-tumor mechanism of the probiotics is to accurately adjust the immune system.

The invention discloses a construction method of an in-vitro liver cancer liver invasion and metastasis experimental model, and relates to the technical field of model construction, and the construction method comprises the following steps: culturing liver cancer cells and hepatic stellate cells, carrying out fluorescence labeling, generating a space coordinate set by using the fluorescence labeled liver cancer cells and hepatic stellate cells, and calculating the in-vitro liver cancer liver invasion and metastasis experimental model. The method comprises the following steps of: printing liver cancer cells and hepatic stellate cells according to a space coordinate set to generate a three-dimensional cell-matrix structure, pouring photoresponse hydrogel into the three-dimensional cell-matrix structure, and inducing HOTAIR long non-coding RNA concentration by using a transforming growth factor to obtain the three-dimensional cell-matrix structure integrated with the photoresponse hydrogel. The space coordinate set is generated through the Markov model, accurate simulation of radial distribution of the highly invasive liver cancer cell core area and the hepatic stellate cells is achieved, and an accurate position template is provided for printing of a three-dimensional cell-matrix structure.

The invention relates to the field of biological medicine, and discloses application of GABRR1 as a tumor marker and a target molecule. According to the application disclosed by the invention, the GABRR1 is discovered as a marker of tumor invasion and metastasis for the first time and participates in growth and invasion and metastasis processes of tumors, so that the GABRR1 can be used as a target spot in diagnosis and / or treatment of the tumors; according to the invention, the GABRR1 protein is used as a tumor target for screening to obtain a monoclonal antibody, a polypeptide or a small molecule drug and other tumor treatment drugs capable of overexpressing GABRR1.

The application relates to an ovary organ chip, a manufacturing method and application thereof. The ovary organ chip is sealed by a four-layer structure from top to bottom, and comprises an upper ovary chip layer, a follicle culture layer, a porous filter membrane layer and a lower ovary chip layer. An upper end of an upper culture medium perfusion chamber of the upper ovary chip layer is communicated with an upper inlet pool through an upper perfusion channel, and a lower end of the upper culture medium perfusion chamber is communicated with an upper outlet pool through the upper perfusion channel. An upper end of a lower culture medium perfusion chamber of the lower ovary chip layer is communicated with a lower inlet pool through a lower perfusion channel, and a lower end of the lower culture medium perfusion chamber is communicated with a lower outlet pool through the lower perfusion channel. The follicle culture layer is provided with a round hole or a cylinder. The ovary organ chip is constructed to simulate the physiological environment and pathological changes of substantial cells in an ovary in vitro, so that researches on hormone synthesis, ovary development and maturation, disease occurrence mechanism, tumor occurrence, development, invasion and metastasis and the like are carried out, and the ovary organ chip is used for researching and developing drugs, individualized treatment of tumors and fertility preservation.

The present invention relates to the field of biomedicine and discloses the application of GABRR1 as a tumor marker and a target molecule. The present invention firstly discovers that GABRR1 serves as a marker for tumor invasion and metastasis and participates in the processes of tumor growth, invasion and metastasis. Therefore, GABRR1 can be used as a target in the diagnosis and / or treatment of tumors; the present invention uses the GABRR1 protein as a tumor target to screen tumor therapeutic drugs such as monoclonal antibodies, polypeptides or small molecule drugs that can overexpress GABRR1.

The invention belongs to the technical field of biological medicine, and relates to application of PARVA as a target spot in lung cancer prevention and treatment. Specifically, the invention provides application of PARVA in preparation of drugs for treating or preventing lung cancer and application of PARVA in reagents or kits for diagnosis or prognosis evaluation of lung cancer. The invention further provides a lung cancer treatment medicine or a lung cancer prevention medicine taking PARVA as a target spot and a kit which comprises a reagent for detecting PARVA mRNA or protein expression and is used for lung cancer diagnosis or lung cancer prognosis evaluation. The invention provides application of PARVA as a target spot in prevention and treatment of lung cancer, and lung cancer cell proliferation, invasion and metastasis and tumor angiogenesis are inhibited by regulating and controlling expression or functions of PARVA in lung cancer cells and tumor microenvironment, so that effective treatment, early diagnosis, recurrence prevention and prognosis evaluation of lung cancer are realized.

The invention relates to the technical field of biology, discloses application of FMNL1 malonylation modification in inhibition of ccRCC transfer, and inhibits ccRCC transfer and invasion by promoting the FMNL1 malonylation modification level. The malonylation modification site of the FMNL1 is located at the 852 site of the FH2 functional structure domain; the malonylation modification level of lysine at the 852 site of the FMNL1FH2 functional structural domain is promoted, and migration and invasion of ccRCC are inhibited. According to the application of the FMNL1 malonylation modification in inhibition of ccRCC metastasis, in-vivo and in-vitro tests verify that the FMNL1 malonylation modification level can inhibit ccRCC invasion and metastasis, so that FMNL1 malonylation is a key target spot for regulating ccRCC invasion and metastasis, and based on the target spot, drugs for inhibiting renal clear cancer cell metastasis can be researched and developed.

The application discloses an oncogene VGLL1 and application of a protein coded by the oncogene VGLL1, and particularly discloses application of a VGLL1 gene and / or a coded protein thereof in preparation of a medicine for treating cancer, and application of the VGLL1 gene and / or the coded protein thereof in preparation of a reagent or a kit for cancer diagnosis and / or prognosis judgment. It is found in the application that the oncogene VGLL1 has an important role in the occurrence and development process of tumors, and high expression of VGLL1 can induce malignant progression such as invasion and metastasis of ovarian cancer. It is also found in the research result that conditionally down-regulating VGLL1 can effectively relieve the growth of ovarian cancer cells and inhibit the invasion and metastasis ability of the ovarian cancer cells. The application provides a new diagnosis and treatment idea and a drug screening platform for solving clinical problems such as metastasis of ovarian cancer.

The invention provides an anti-tumor composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The anti-tumor composition disclosed by the invention is prepared from the following raw materials in parts by mass: 18 to 22 parts of ginsenoside Rg3, 3 to 7 parts of ginsenoside CK, 28 to 32 parts of ganoderma lucidum polysaccharide, 23 to 27 parts of astragalus polysaccharide, 8 to 12 parts of lentinan, 16 to 20 parts of panax notoginseng saponins, 9 to 11 parts of resveratrol, 13 to 17 parts of curcumin, 6 to 10 parts of dihydromyricetin and 7 to 9 parts of sophocarpidine. The ratio of the total mass of the ganoderan and the astragalus polysaccharide to the total mass of the ginsenoside Rg3 and the panax notoginseng saponins is (1.3-1.6): 1. Through a multi-target and multi-path synergistic effect mechanism, tumor cell proliferation can be directly inhibited, apoptosis can be induced, the cell cycle can be retarded, tumor angiogenesis can be inhibited, the immune function of the body can be enhanced, the antioxidant effect can be exerted, tumor invasion and metastasis can be inhibited, meanwhile, the obvious synergistic and toxicity reducing effects can be shown in combined chemotherapy application, and the application prospect is wide. And a new technical scheme is provided for comprehensive treatment of tumors.

The application discloses application of a substance for inhibiting expression of ZNF8 protein in preparation of a product for preventing and treating cancer. Experiments prove that the ZNF8 protein can be combined with p53 protein; the expression of the ZNF8 protein can increase transcriptional activity of the p53 protein, down-regulate expression of VEGF gene and ANGPLT4 gene, inhibit proliferation of tumor cells, inhibit migration of tumor cells, inhibit transfer of tumor cells, inhibit invasion and transfer of tumor cells, inhibit formation of blood vessels, inhibit growth of tumors, inhibit transfer of tumors, inhibit lung transfer of tumors and improve survival rate of tumor-bearing animals, so that the expression of the ZNF8 protein has important application value in inhibition of growth and invasion and transfer of tumors; the expression of the ZNF8 protein can prevent and treat cancer.

The present application provides the application, method and drug related to the regulation of tumor or inflammatory disease related macrophage infiltration by CREPT. The present application also provides the application of the inhibition of CREPT positive tumor associated macrophage (TAM) in the preparation of the preparation for regulating the tumor microenvironment, and the application in the preparation of the drug for treating tumor or promoting the action of T lymphocyte. The inhibition of the CREPT positive tumor associated macrophage (TAM) can provide a technical means for controlling tumor proliferation, invasion and metastasis. The CREPT positive tumor associated macrophage (TAM) can also be used as a biomarker for the risk of an individual suffering from tumor, or a biomarker for the development stage of the tumor of an individual, to judge the risk of an individual suffering from tumor or the stage and progress of the tumor of a tumor patient.

The invention discloses a CDKN2A and ISG15 interaction key site MET53 and an application of the CDKN2A and ISG15 interaction key site MET53. In particular to application of a CDKN2A protein MET53 site in preparation of products for diagnosing or inhibiting tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level and a method for preparing cancer cells with inhibited invasion and metastasis capacity, and provides a new way for precise diagnosis and treatment of tumors. The important clinical application value is realized.

The use of Campylobacter jejuni and its toxin in the preparation of drugs for preventing, diagnosing, predicting, treating colorectal cancer and extra-intestinal tumor metastasis. Campylobacter, especially Campylobacter jejuni and toxin CDT, can be used as a marker to distinguish whether a colorectal cancer patient has metastasis. Experiments have proved that Campylobacter jejuni has the ability to promote metastasis and invasion. Campylobacter jejuni promotes the invasion and metastasis of colon cancer cells by CDT protein and the up-regulated JAK2 / STAT3 / MMP9 signaling pathway activated by CDT protein. When the process is blocked, the tumor metastasis-promoting ability of Campylobacter jejuni is weakened or lost. Campylobacter jejuni also promotes the metastasis of extra-intestinal tumors. Based on drugs or agents that can block this process, the metastasis of colorectal cancer cells and extra-intestinal tumors can be prevented and inhibited. Based on Campylobacter jejuni and its toxin, corresponding reagents or methods are developed for diagnosing or predicting the metastasis of colorectal cancer and extra-intestinal tumors. Through the marker provided in the present application, it is expected to inhibit tumor metastasis and prolong the survival of patients.

The invention discloses application of piR-11510 in diagnosis, treatment and prognostic evaluation of non-small cell lung cancer bone metastasis, and belongs to the technical field of biological medicine. Based on the research of the invention, the piR-11510 can be used as a diagnostic marker of non-small cell lung cancer bone metastasis; the piR-11510 can also be used as a treatment target of non-small cell lung cancer bone metastasis, and targeted intervention of the piR-11510 can inhibit proliferation, invasion, metastasis and / or colonization of non-small cell lung cancer cells. Therefore, the piR-11510 is a potential molecular marker for specific diagnosis of non-small cell lung cancer bone metastasis, can be rapidly detected through a blood sample, and has good clinical value for diagnosis of non-small cell lung cancer bone metastasis and development of a clinical precise treatment scheme.

The application provides application of SLC6A12 in a diagnostic marker and / or a therapeutic target of liver cancer metastasis, and belongs to the technical field of disease diagnosis or biological medicine. The application provides application of SLC6A12 gene and / or SLC6A12 protein in a diagnostic marker and / or a therapeutic target of liver cancer metastasis. The application detects that SLC6A12 gene or SLC6A12 protein is differentially expressed in situ liver cancer and liver cancer metastatic tumor from the clinical liver cancer patient and animal level respectively, and the expression amount is significantly increased in the liver cancer metastatic tumor. The application can obviously reduce the invasion and metastasis ability of liver cancer cells in a primary liver cancer mouse model by knocking down the expression of SLC6A12 gene and / or SLC6A12 protein. Therefore, the application of SLC6A12 gene or protein as a marker and a therapeutic target in liver cancer metastasis provides a new idea for the diagnosis and treatment of liver cancer metastasis.

The invention relates to the field of biological medicine, in particular to application of IL4i1 serving as a marker to prediction of neck lymph node metastasis of papillary thyroid cancer and application of IL4i1 serving as a treatment target to preparation of medicine for inhibiting thyroid cancer lymph node invasion and metastasis. The invention provides a biomarker IL4i1 for predicting thyroid cancer lymph node metastasis, and reveals that invasion and metastasis of tumors will be effectively inhibited by reducing expression of the IL4i1. The conclusion of the invention provides theoretical support and technical guarantee for accurate diagnosis of lymph node metastasis and disease progression of patients, and also provides strategy guidance for personalized medical schemes.

The invention belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein 301 site as a target spot in preparation or screening of anti-triple-negative breast cancer drugs. According to the invention, the SNIP1 protein is found to be a non-histone substrate of lysine methyltransferase KMT5A, and the SNIP1 protein promotes growth, invasion and lung metastasis of breast cancer cells through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening anti-tumor drugs, and the screened drugs for inhibiting methylation of the K301 site of the SNIP1 protein can be used for resisting tumors; the invention further provides a polypeptide specifically bound with the K301 site of the SNIP1 protein, the polypeptide is bound with the K301 site of the SNIP1 protein, methylation of the SNIP1 is inhibited, finally, growth, proliferation, invasion and metastasis of tumors can be inhibited, and the polypeptide can be used as a novel targeted anti-tumor drug.

The invention discloses an application of scurriboside B or a derivative thereof in preparation of a medicine for treating gastric cancer. The structure of the scurriboside B is shown in the specification. The Sanbao lignin B or the derivative of the Sanbao lignin B down-regulates expression of invasion and metastasis related protein, inhibits migration and invasion of gastric cancer cells, reduces the risk of tumor distant metastasis and blocks malignant progression of gastric cancer by regulating an EMT related signal channel. Aiming at the pain points of low proportion of HER2 positive patients, easy generation of drug resistance of targeted drugs, limited immune treatment benefit crowds and the like in current gastric cancer treatment, the Sancurbatin B as a brand new natural anti-tumor active component provides a new candidate target and direction for research and development of anti-gastric cancer drugs. The compound not only can be independently developed into an anti-gastric cancer drug, but also can be used in combination with chemotherapy, targeted therapy or immunotherapy drugs to synergistically improve the treatment effect, and has extremely high clinical transformation value and market application potential.